KRAS and colorectal carcinoma: The effectiveness of KYA1797K but not cetuximab on the inhibition of the growth and transformation of cells harboring KRAS mutations was confirmed by comparing WT- and MT-KRAS CRC cells (Fig. 3b, c; Supplementary Figure S4a and b).